Psychedelics biotech BetterLife Pharma Inc. (OTCQB:BETRF) is fast-tracking its U.S. patent application covering the composition of matter, treatment uses and a novel production method of non-hallucinogenic LSD derivatives including the company's 2-bromo-LSD derivative BETR-001 which is expected to begin clinical trials for Major Depressive Disorder (MDD.)
The proprietary manufacturing method for non-hallucinogenic LSD derivatives would not involve the use of strictly controlled intermediate substances.
Meanwhile, their use protection includes treatment around several neuropsychiatric and neurological conditions such as depression, anxiety, cluster headaches and neuropathic pain.
CEO Dr. Ahmad Doroudian says that facing 2-bromo-LSD's originally suspected neuropharmacological inactivity as compared to LSD, BetterLife was able to show the compound has "robust" neuroplasticity properties as well as efficacy in preclinical models of depression, anxiety and pain.
Composition claims within the new patent applications also cover the different polymorphs and pharmacological properties of 2-bromo-LSD's stereoisomers, which the company believes are "strong" and that "will hold the test of time, much like we are seeing how similar composition patents for molecules like S- and R-ketamine, psilocybin polymorphs and so forth, although challenged, have been upheld by the USPTO."
See also: This Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History
Another biotech company recently fast-tracked an application covering the use of its proprietary racemic ketamine: PharmaTher Holdings (OTC:PHRRF) submitted a petition to the FDA on the use of its KETARX for the treatment of levodopa-induced dyskinesia in Parkinson's disease back in May.
See also: Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Photo: Benzinga edit with photo by Olia Danilevich on Pexels.